<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00596583</url>
  </required_header>
  <id_info>
    <org_study_id>AQNA-DY001</org_study_id>
    <secondary_id>US IND 75,735</secondary_id>
    <nct_id>NCT00596583</nct_id>
  </id_info>
  <brief_title>DY001: Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery</brief_title>
  <official_title>AQNA-DY001: A Double-Masked, Randomized Study of the Safety and Effectiveness of DYME as an Agent for Selective Staining of the Anterior Capsule During Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Aqumen Biopharmaceuticals, N.A.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Aqumen Biopharmaceuticals, N.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The primary objective of this study is to test the hypothesis that DYME is safe and effective
      as a drug to facilitate continuous curvilinear capsulorhexis (CCC) by selectively staining
      the anterior capsule. Secondary objectives are to compare the safety and effectiveness of
      DYME to that of a smaller dose of the same API.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">May 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Optimal curvilinear capsulorrhexis with a single dose, as assessed by the surgeon based on the tissue dyed and subsequently removed.</measure>
    <time_frame>During surgery</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Uncomplicated discharge</measure>
    <time_frame>one week post-op</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of stain</measure>
    <time_frame>during surgery</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Intra-ocular safety of DYME as measured by best corrected visual acuity, corneal endothelial cell count, intraocular pressure, presence/absence of retained dye, duration of surgery, and the absence of dye related adverse events</measure>
    <time_frame>1-day and 1-week post-op</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Mature Cataracts</condition>
  <arm_group>
    <arm_group_label>High Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Low Dose</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DYME</intervention_name>
    <description>2ml of 0.25 mg/ml BBG 250 in sterile ophthalmic solution</description>
    <arm_group_label>High Dose</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>DYME</intervention_name>
    <description>2ml of 0.05 mg/ml BBG 250 in sterile ophthalmic solution</description>
    <arm_group_label>Low Dose</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Have a cataract sufficiently opaque/mature/brunescent that, in the surgeon's
             assessment,a dye could facilitate surgery;

          -  Be aged at least 18 years old at the time of enrollment;

          -  Be able to tolerate a surgical procedure for up to 3 hours;

          -  Be in a medical condition suitable for cataract surgery;

          -  Able and willing to participate in study examinations and visit schedule; and

          -  Understand and freely consent to participate in the study.

        Exclusion Criteria:

          -  In either eye, ocular infection or inflammation within the past 3 months;

          -  Known allergy to BBG 250;

          -  Uncontrolled intercurrent diseases including, but not limited to, ongoing or active
             infection, symptomatic congestive heart failure, unstable angina pectoris, or cardiac
             arrhythmia;

          -  Active treatment for cancer or systemic infection within the past month;

          -  Active treatment with systemic corticosteroids within the past month;

          -  Previous participation in this Study for the contralateral eye;

          -  Participation in another clinical trial involving an investigational therapeutic
             during the past 30 days or 5.5 half-lives (if applicable), whichever is longer;

          -  Unwillingness to participate in the study or inability to give informed consent; or

          -  Any medical condition that in the opinion of the Investigator may compromise the
             research subject's safety or ability to participate in the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hardy Kagimoto, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Aqumen Biopharmaceuticals, N.A.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>McDonald Eye Associates</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Peace Laser Eye Center</name>
      <address>
        <city>Inglewood</city>
        <state>California</state>
        <zip>90301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Capitol City Surgery Center</name>
      <address>
        <city>Sacramento</city>
        <state>California</state>
        <zip>95815</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Eye Institute of West Florida</name>
      <address>
        <city>Largo</city>
        <state>Florida</state>
        <zip>33770</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Excellence in Eye Care</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33176</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Surgeons of Indiana</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46256</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Silverstein Eye Centers</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64133</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. John's Clinic Eye Specialists</name>
      <address>
        <city>Springfield</city>
        <state>Missouri</state>
        <zip>65804</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ballas Surgery Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63141</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Surgery Center</name>
      <address>
        <city>Cherry Hill</city>
        <state>New Jersey</state>
        <zip>08002</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Brar-Parekh Eye Associates</name>
      <address>
        <city>West Paterson</city>
        <state>New Jersey</state>
        <zip>07424</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Island Eye Surgicenter</name>
      <address>
        <city>Carle Place</city>
        <state>New York</state>
        <zip>11514</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Ohio State University Hospital</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Eye Care Specialists</name>
      <address>
        <city>Kingston</city>
        <state>Pennsylvania</state>
        <zip>18704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Eye Surgery Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wills Surgery Center</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19145</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>SMDV Surgery Center</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53715</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Nethralaya</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560020</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bhagwan Mahaveer Jain Hospital</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560052</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Narayana Nethralaya</name>
      <address>
        <city>Bangalore</city>
        <state>Karnataka</state>
        <zip>560099</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Mehta International Eye Institute &amp; Colaba Eye Hospital</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 005</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bombay City Eye Institute &amp; Research Centre</name>
      <address>
        <city>Mumbai</city>
        <state>Maharashtra</state>
        <zip>400 007</zip>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2009</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 9, 2008</study_first_submitted>
  <study_first_submitted_qc>January 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 17, 2008</study_first_posted>
  <last_update_submitted>February 27, 2009</last_update_submitted>
  <last_update_submitted_qc>February 27, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 2, 2009</last_update_posted>
  <responsible_party>
    <name_title>Hardy Kagimoto, M.D. / C.E.O.</name_title>
    <organization>Aqumen Biopharmaceuticals, N.A.</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ophthalmic Solutions</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

